Autres langues Positive Group

Actions

POSI

RU000A103X66

Cours en clôture Moscow Micex - RTS Autres places de cotation 00:00:00 08/07/2022			Varia. 5j.	Varia. 1 janv.
869,6 ^RUB	+0,65 %		-.--%	-.--%

26/04	Public Joint Stock Company Positive Group annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
10/04	Public Joint Stock Company Positive Group publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Public Joint Stock Company Positive Group Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04
Public Joint Stock Company Positive Group Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Public Joint Stock Company Positive Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Public Joint Stock Company Positive Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	26/07/23
Public Joint Stock Company Positive Group Reports Earnings Results for the First Quarter Ended March 31, 2023	30/04/23
Public Joint Stock Company Positive Group Reports Earnings Results for the Full Year Ended December 31, 2022	04/04/23
Certain Ordinary Shares of Public Joint Stock Company Positive Group are subject to a Lock-Up Agreement Ending on 29-MAR-2023.	29/03/23
Draftkings Positive Group Dynamics Supports Long-term Margin Targets if More States Legalize Gambling, Oppenheimer Says	11/04/22
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	04/11/21
Innovent Biologics, Inc. Announces National Medical Products Administration of China Accepts the Supplemental New Drug Application	04/11/21
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	16/08/21
Stoxx Europe 600 : European Stocks End Lower Ahead of US Fed Minutes	19/05/21
Porsche Automobil : Q1 Profit Grows Tenfold On Volkswagen Investment	19/05/21
Bastei Lübbe AG Announces Earnings Guidance for the Year 2020	12/11/20
Gesco AG Revises Earnings Guidance for the Year 2020	03/08/20
Viela Bio Announces U.S. FDA Approval of Uplizna (Inebilizumab-Cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder	11/06/20
Corvus Pharmaceuticals, Inc. Announces Updated Results from Its Phase 1B/2 Clinical Trial of Ciforadenant	29/05/20
Hansa Biopharma Announces Long Term Follow-Up Data That Demonstrates 2-Year Graft Survival of 89% After Imlifdase Treatment and Transplantation	06/03/20
Corvus Pharmaceuticals, Inc. Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer Annual Meeting	08/11/19
Resimac Group Ltd acquired 15% stake in Positive Group Australia Pty Ltd for AUD 3 million.	03/07/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Positive Group

Actions

POSI

RU000A103X66

Autres langues

Filtres